Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
Interesting Engineering on MSN19h
US approves first nasal spray for major depressive disorder, PTSD conditionsJohnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback